Skip to content

Integra LifeSciences IART Specialty Surgery — Cost of goods sold

Other segment segments

Tissue Reconstruction
$37.46M

Similar metrics at other companies

LKQ logo
LKQSpecialty — Cost of goods sold
$310M+3.7%
Amneal Pharmaceuticals, Inc. logo
AMRXSpecialty — Cost of goods sold
$43.02M-19.0%
Perrigo Company logo
PRGOSpecialty Care — Cost of Sales
$92.8M+13.0%
Stepan logo
SCLSpecialty Products — Cost of Goods Sold
$15.17M+45.9%
Amneal Pharmaceuticals, Inc. logo
AMRXSpecialty — Cost of Goods Sold
$61.48M+21.2%
Perimeter Solutions logo
PRMSpecialty Products — Adjusted cost of goods sold
$45.29M+100%

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's specialty surgery — cost of goods sold.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's specialty surgery — cost of goods sold?
Integra LifeSciences (IART) reported specialty surgery — cost of goods sold of $110.48M in Q1 2026.
What does specialty surgery — cost of goods sold mean?
This represents the direct costs attributable to the production and delivery of medical products within the Specialty Surgery segment. Monitoring this metric is essential for assessing manufacturing efficiency and the direct impact of supply chain costs on segment-level gross margins.